Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 8/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 8/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798344 | 1.00 | TBXAS1 (0.45) | TBXAS1CYP4F2CYP4A11CYP2C19CPB2 | |
| SCHEMBL798200 | 1.00 | TBXAS1 (0.45) | TBXAS1CYP4F2CYP4A11CYP2C19CPB2 | |
| SCHEMBL798204 | 1.00 | TBXAS1 (0.45) | TBXAS1CYP4F2CYP4A11CYP2C19CPB2 | |
| SCHEMBL17099452 | 0.93 | CYP4F2 (0.53) | TBXAS1CYP4F2CYP4A11CYP2C19CPB2 | |
| SCHEMBL10257161 | 0.93 | CYP4F2 (0.53) | TBXAS1CYP4F2CYP4A11CYP2C19CPB2 | |
| SCHEMBL798202 | 0.90 | TBXAS1 (0.54) | TBXAS1CYP4F2CYP4A11CYP2C19CPB2 | |
| SCHEMBL798439 | 0.90 | TBXAS1 (0.50) | TBXAS1CYP4F2CYP4A11CYP2C19CPB2 | |
| SCHEMBL9182194 | 0.90 | TBXAS1 (0.54) | TBXAS1CYP4F2CYP4A11CYP2C19CPB2 | |
| SCHEMBL11226563 | 0.90 | CYP4F2 (0.50) | TBXAS1CYP4F2CYP4A11CYP2C19FFAR3 | |
| SCHEMBL23533401 | 0.89 | GPR84 (0.43) | TBXAS1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433858-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | NEPHRODI THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-20240139127-A1 | SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS | NEPHRODI THERAPEUTICS, INC. | 2024-05-02 | — | — | US | claimed |
| US-11844770-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | NEPHRODI THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | claimed |
| US-20230364039-A1 | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy | UNIV EMORY (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364039-A1 | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy | UNIV EMORY (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4228754-A1 | METHODS OF MANAGING SIDE EFFECTS OF A VASOPRESSIN RECEPTOR ANTAGONIST THERAPY | Emory University (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081858-A1 | METHODS OF MANAGING SIDE EFFECTS OF A VASOPRESSIN RECEPTOR ANTAGONIST THERAPY | EMORY UNIVERSITY (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220031639-A1 | SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS | NEPHRODI THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11179354-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | NEPHRODI THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200383940-A1 | Managing Nephrogenic Diabetes Insipidus | EMORY UNIVERSITY | 2020-12-10 | — | — | US | disclosed |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-8623897-B2 | Methods and compositions for treatment of diabetes and dyslipidemia | KAREUS THERAPEUTICS, SA (CH) | 2014-01-07 | — | — | US | disclosed |
| US-8623897-B2 | Methods and compositions for treatment of diabetes and dyslipidemia | KAREUS THERAPEUTICS, SA (CH) | 2014-01-07 | — | — | US | disclosed |
| WO-2012040177-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139127-A1 | SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS | SLC5A2, SLC5A1, IAPP | TBXAS1 1451/4885CYP4F2 1224/4885CYP4A11 209/4885 |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | LIPC, PNLIP, LIPA | TBXAS1 555/4885CYP4F2 361/4885CYP4A11 66/4885 |
| US-11844770-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | SLC5A2, SLC5A1, IAPP | TBXAS1 2042/4885CYP4F2 2194/4885CYP4A11 342/4885 |
| US-20230364039-A1 | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy | AVPR2, AVPR1A, AVPR1B | TBXAS1 3168/4885CYP4F2 4874/4885CYP4A11 4735/4885 |
| US-20220031639-A1 | SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS | SLC5A2, SLC5A1, IAPP | TBXAS1 1451/4885CYP4F2 1224/4885CYP4A11 209/4885 |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | GPR119, FFAR1, INSR | TBXAS1 716/4885CYP4F2 1151/4885CYP4A11 145/4885 |
| US-20200383940-A1 | Managing Nephrogenic Diabetes Insipidus | SLC5A2, SLC5A1, IAPP | TBXAS1 2555/4885CYP4F2 1726/4885CYP4A11 363/4885 |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | DHCR7, INSR, GPR119 | TBXAS1 1595/4885CYP4F2 1069/4885CYP4A11 289/4885 |
| US-11179354-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | SLC5A2, SLC5A1, IAPP | TBXAS1 1392/4885CYP4F2 1133/4885CYP4A11 211/4885 |
| US-12433858-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | SLC5A1, SLC5A2, IAPP | TBXAS1 2129/4885CYP4F2 2358/4885CYP4A11 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.